Literature DB >> 22042251

How to connect an IgE-driven response with CTL activity?

Barbara Platzer1, Eleonora Dehlink, Shannon J Turley, Edda Fiebiger.   

Abstract

One of the goals of cell-based immune therapy in cancer is the induction of tumor-specific cytotoxic T-lymphocyte (CTL) responses. To achieve this objective, the ability of dendritic cells (DC) to cross-present tumor antigens can be exploited. One of the most efficient pathways for the induction of CTLs by cross-presentation is mediated by immunoglobulins of the IgG class, which are used by DCs to sample antigen in the form of immune complexes via Fc-gamma receptors. Could DCs use an IgE-mediated cross-presentation mechanism in a comparable manner to induce CTLs? We here discuss the potential of two human IgE Fc receptors, FcεRI and FcεRII, to serve as antigen uptake receptors for IgE-mediated cross-presentation. We conclude that the existence of an IgE-mediated cross-presentation pathway would provide a direct link between IgE-driven immune responses and CTL activity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22042251      PMCID: PMC3299812          DOI: 10.1007/s00262-011-1127-y

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  38 in total

Review 1.  Fc receptors for IgG and antigen presentation on MHC class I and class II molecules.

Authors:  S Amigorena; C Bonnerot
Journal:  Semin Immunol       Date:  1999-12       Impact factor: 11.130

2.  Expression of Fc epsilon receptor I on primary sensory neurons in mice.

Authors:  Tsugunobu Andoh; Yasushi Kuraishi
Journal:  Neuroreport       Date:  2004-09-15       Impact factor: 1.837

Review 3.  Fc receptors.

Authors:  J V Ravetch; J P Kinet
Journal:  Annu Rev Immunol       Date:  1991       Impact factor: 28.527

Review 4.  Soluble IgE receptors--elements of the IgE network.

Authors:  Barbara Platzer; Floortje Ruiter; John van der Mee; Edda Fiebiger
Journal:  Immunol Lett       Date:  2011-09-06       Impact factor: 3.685

5.  Effector CD8+ T cells mediate inflammation and airway hyper-responsiveness.

Authors:  Nobuaki Miyahara; Bradley J Swanson; Katsuyuki Takeda; Christian Taube; Satoko Miyahara; Taku Kodama; Azzeddine Dakhama; Vanessa L Ott; Erwin W Gelfand
Journal:  Nat Med       Date:  2004-07-18       Impact factor: 53.440

6.  Antigen focusing by specific monomeric immunoglobulin E bound to CD23 on Epstein-Barr virus-transformed B cells.

Authors:  L F Santamaria; R Bheekha; F C van Reijsen; M T Perez Soler; M Suter; C A Bruijnzeel-Koomen; G C Mudde
Journal:  Hum Immunol       Date:  1993-05       Impact factor: 2.850

Review 7.  Immunoglobulin E-binding structures on antigen-presenting cells present in skin and blood.

Authors:  D Maurer; G Stingl
Journal:  J Invest Dermatol       Date:  1995-05       Impact factor: 8.551

8.  Antitumor monoclonal antibodies enhance cross-presentation ofcCellular antigens and the generation of myeloma-specific killer T cells by dendritic cells.

Authors:  Kavita M Dhodapkar; Joseph Krasovsky; Barbara Williamson; Madhav V Dhodapkar
Journal:  J Exp Med       Date:  2002-01-07       Impact factor: 14.307

9.  Constitutive versus activation-dependent cross-presentation of immune complexes by CD8(+) and CD8(-) dendritic cells in vivo.

Authors:  Joke M M den Haan; Michael J Bevan
Journal:  J Exp Med       Date:  2002-09-16       Impact factor: 14.307

10.  Expression of functional high affinity immunoglobulin E receptors (Fc epsilon RI) on monocytes of atopic individuals.

Authors:  D Maurer; E Fiebiger; B Reininger; B Wolff-Winiski; M H Jouvin; O Kilgus; J P Kinet; G Stingl
Journal:  J Exp Med       Date:  1994-02-01       Impact factor: 14.307

View more
  11 in total

1.  Association between allergies and risk of pancreatic cancer.

Authors:  Michelle Cotterchio; Elizabeth Lowcock; Thomas J Hudson; Celia Greenwood; Steven Gallinger
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-02-19       Impact factor: 4.254

Review 2.  Cross-presentation of IgG-containing immune complexes.

Authors:  Kristi Baker; Timo Rath; Wayne I Lencer; Edda Fiebiger; Richard S Blumberg
Journal:  Cell Mol Life Sci       Date:  2012-07-31       Impact factor: 9.261

3.  The nascent field of AllergoOncology.

Authors:  Erika Jensen-Jarolim; Graham Pawelec
Journal:  Cancer Immunol Immunother       Date:  2012-08-22       Impact factor: 6.968

4.  Human schistosome infection and allergic sensitisation.

Authors:  Nadine Rujeni; David W Taylor; Francisca Mutapi
Journal:  J Parasitol Res       Date:  2012-08-27

Review 5.  IgE-based immunotherapy of cancer: challenges and chances.

Authors:  J Singer; E Jensen-Jarolim
Journal:  Allergy       Date:  2013-10-14       Impact factor: 13.146

Review 6.  AllergoOncology - the impact of allergy in oncology: EAACI position paper.

Authors:  E Jensen-Jarolim; H J Bax; R Bianchini; M Capron; C Corrigan; M Castells; D Dombrowicz; T R Daniels-Wells; J Fazekas; E Fiebiger; S Gatault; H J Gould; J Janda; D H Josephs; P Karagiannis; F Levi-Schaffer; A Meshcheryakova; D Mechtcheriakova; Y Mekori; F Mungenast; E A Nigro; M L Penichet; F Redegeld; L Saul; J Singer; J F Spicer; A G Siccardi; E Spillner; M C Turner; E Untersmayr; L Vangelista; S N Karagiannis
Journal:  Allergy       Date:  2017-01-23       Impact factor: 13.146

Review 7.  IgE immunotherapy: a novel concept with promise for the treatment of cancer.

Authors:  Debra H Josephs; James F Spicer; Panagiotis Karagiannis; Hannah J Gould; Sophia N Karagiannis
Journal:  MAbs       Date:  2014 Jan-Feb       Impact factor: 5.857

8.  Establishing the role of tyrosine kinase 2 in cancer.

Authors:  Caroline Ubel; Stephanie Mousset; Denis Trufa; Horia Sirbu; Susetta Finotto
Journal:  Oncoimmunology       Date:  2013-01-01       Impact factor: 8.110

Review 9.  Antigen cross-presentation of immune complexes.

Authors:  Barbara Platzer; Madeleine Stout; Edda Fiebiger
Journal:  Front Immunol       Date:  2014-04-01       Impact factor: 7.561

Review 10.  The Role of FcRn in Antigen Presentation.

Authors:  Kristi Baker; Timo Rath; Michal Pyzik; Richard S Blumberg
Journal:  Front Immunol       Date:  2014-08-27       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.